TABLE 1.
Mortality data in patients with hematological cancers, participants in early‐phases clinical trials (Phases 1 and 2), between 2008 and 2023.
| Tumor type categories (n patients) | All patients (736) | DLBCL (253) | AML/MDS (164) | Myeloma (100) | Indolent lymphoma (78) | PTCL (45) | Hodgkin (40) | MCL (32) | MF (20) | Other (4) |
|---|---|---|---|---|---|---|---|---|---|---|
| Mortality ≤ Day 30 | 20 (2.72%) | 9 (3.56%) | 7 (4.26%) | 0 | 1 (1.28%) | 2 (4.44%) | 0 | 1 (3.12%) | 0 | 0 |
| Mortality ≤ Day 90 | 101 (13.72%) | 39 (15.41%) | 38 (23.17%) | 4 (4.00%) | 3 (3.84%) | 9 (20.00%) | 1 (2.5%) | 6 (18.75%) | 1 (5.00%) | 0 |
| Death on‐protocol, as reason of end of protocol | 40 (5.43%) | 1 (0.39%) | 38 (23.17%) | 0 | 1 (1.28%) | 0 | 0 | 0 | 0 | 0 |
| Death related to study drug | 4 (0.54%) | 1 (0.39%) | 2 (1.21%) | 0 | 1 (1.28%) | 0 | 0 | 0 | 0 | 0 |
Note: The table reports the overall mortality rates in the first 30 and 90 days after the start of the protocol, mortality during the protocol (regardless of causality with the protocol treatment) and mortality due to toxic events related to the protocol treatment. Data presented are n (%) unless otherwise stated. Percentages are expressed compared with the total number of patients in each disease category.
Abbreviations: AML, acute myeloid leukemia; DLBCL, diffuse large B cell lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MF, Myelofibrosis; PTCL, peripheral T cell lymphoma.